LTHOUGH brain tumors account for only 3 % of the deaths from malignant disease in the United States 5 and the results of surgical treatment and irradiation have generally been unsuccessful, 1,2,7,9,~ interest in their management has continued unabated. Chemotherapy has been underutilized as an investigative and therapeutic tool because of the pharmacophysiological peculiarities of cerebral tissue. To pass through the blood-brain barrier, an agent must possess a high degree of lipid solubility, a relatively small molecular size, and a low degree of ionization. TM The failure of many chemotherapeutic attempts may have been related to their not possessing these idealized characteristics as well as to their lack of specific cytoactivity. ~,1~
The agent 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) (CCNU) is a derivative of 1-methyl-l-nitrosourea (NSC 23909). At a physiological pH it is highly lipid-soluble, non-ionized, and only partially protein-bound, thus possessing some of the required pharmacological characteristics of a drug able to pass the blood-brain bar-rier. 12,1,~ Its high degree of aqueous insolubility has made oral administration mandatory at the present time. CCNU, like its earlier relative BCNU, is active against a broad spectrum of animal tumor systems, including IC murine leukemia L1210. BCNU has shown symptomatic efficacy in nonrandomized Phase 2 studies in the treatment of malignant brain tumor. 15, 16 However, the long-term intravenous administration of BCNU is complicated by sclerosis of the veins and frequent serious hematological toxicity at the doses used.
CCNU has also shown some activity in a few patients with glioblastoma multiforme 6 and has the potential of being an effective agent for the treatment of brain tumors. This report concerns the use of oral CCNU in a Phase 2 study, the toxicity encountered in its long-term use in a small group of patients, and a preliminary evaluation of its efficacy utilizing a newly devised central nervous system (CNS) disease staging system.
Materials and Methods

Patient Selection
Twenty-six consecutive patients with intracranial malignant disease who were admitted to the Baltimore Cancer Research Center, Section of Neurosurgery, between March, 1970, and July, 1971, were studied. Confirmation of malignant disease by operative reduction of tumor bulk and biopsy was required except in those cases in which operation was contraindicated. Those who had received x-ray therapy more than 1 month previously were considered acceptable for the study, and, except in rare circumstances, patients who had received prior chemotherapy were not accepted for study and treatment. Those who experienced progression of the disease while on corticosteroids or required fixed maintenance doses of corticosteroids were not excluded from the study. Normal pretreatment complete blood counts (CBC's), including platelet counts and normal hepatic and renal function, were mandatory.
Drug Administration and Supportive Measures
CCNU was supplied by the Cancer Chemotherapy National Service, NCI, in gelatin capsules containing 20 or 40 mg of drug. Following evaluation and after informed consent had been obtained, the majority of patients were treated with 130 milligrams per meter squared (mg/m 2) while fasting. After trial at this dose level, several patients received initial doses of 150 mg/m2; however, as the evidence of the cumulative nature of CCNU's hematological toxicity increased this dose was discontinued. One patient (Case 10) was treated with 100 mg/m 2 because of previous total neuraxis radiotherapy.
The same dose was repeated at 6-to 8-week intervals after the return of the platelet count to over 150,000/mm 8. Patients who showed marked platelet count depression (<20,000/mm z) during either the initial or subsequent courses received a 20% reduction in dose; they were cared for as outpatients whenever clinically feasible. However, all patients were hospitalized for observation, and daily platelet counts were obtained whenever the count fell below 20,000/mm 3. Transfusions were given whenever the platelet count decreased to or below 10,000/mm 3 or whenever overt bleeding was observed.
Supportive services such as physical therapy, occupational therapy, and general or intensive nursing care were provided as necessary. All patients were receiving one or more additional drugs during treatment. These were primarily the anticonvulsants diphenylhydantoin and phenobarbital; sedatives or tranquilizers such as pentobarbital, chlorpromazine, or prochlorperazine; medications for pain relief including acetaminophen, pentazocine, or codeine; and antibiotics for certain coincidental infections. Mannitol, urea, or other osmotic dehydrating agents were not used during chemotherapy.
Patient Evaluation
Before each course of therapy, patients were evaluated by neurological examination and disease appraisal, skull films, brain scans (99roTe), and lumbar puncture with CSF analysis for cells, sugar, protein content, and bacterial culture. Laboratory tests included complete blood and platelet count (CBC), hepatic and renal function tests as determined by serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase, lactic dehydrogenase (LDH), bilirubin, blood urea nitrogen (BUN), and electrolytes. In addition, between treatments CBC's were obtained two or three times per week, and blood chemistry examinations were performed weekly or as clinically indicated. Most patients also had bone marrow examinations prior to and during each course of therapy. Clinical evaluations were repeated weekly.
A new central nervous system (CNS) disease staging system was devised because there has been no completely satisfactory quantitative method of evaluating the changes in intracranial mass lesions. The purpose of this system was to obtain a moderately sensitive, reliable, quantitative measurement of each patient's degree of neurological impairment. Utilizing the two interrelated categories of symptoms and function, and signs, a patient was finally placed in one of four stages of clinical CNS disease. The evaluation of symptoms and functions (Table 1 ) contained aspects comparable to the Karnofsky Performance Scale but individualized to the patient with intracranial malignancy, s Symptoms were evaluated according to their severity and activity-limiting nature, and function according to the patient's ability to care for himself and the percentage of normal waking hours spent in bed. Both were individually graded at four levels, from the asymptomatie normallyfunctioning patient of Grade 1, to the most debilitated of Grade 4. If a discrepancy existed between the grading of symptom and function, function was weighted more heavily. Very mild abnormalities were permitted in Grade 1.
The sign grading system (Table 2 ) evaluated the neurological examination; it had eight categories encompassing the majority of important abnormalities found in patients with brain tumors. If another abnormality was present that seemed significant to the evaluation and follow-up, space was available for its inclusion. Each category was graded at four levels, from the absence of defects in Grade 1 to the most marked defects of Grade 4. The final composite sign grade was defined as the highest numbered grade that had defects in two or more categories. As in the symptoms and function section, very mild abnormalities were permitted in Grade 1. Irreversible, stable defects secondary to past events (such as surgery or intracranial hypertension) were noted but not used to obtain the sign grade, as they might have unduly biased the grading system. The final composite Stage of central nervous system disease was defined as the higher numbered grade in either of the basic divisions (Table 3) . A more detailed description of this "staging system" is in preparation.
The response to chemotherapy was evaluated by the disease stage assigned before and after each completed course, so that transient improvement within courses lasting less than a few weeks was excluded from the analysis. Patients evaluated as Stage 1 before and after a treatment course were described as being in "continued well-being" (CW). If a patient improved in disease stage he was considered a "remission" (R), whereas failure to improve was considered as "no change" (NC) and deterioration from any stage was considered as "progression" (P).
Results
Patient Population
Pertinent details of the 26 patients studied are indicated in Table 4 . The tumor types included 19 malignant gliomas, four other primary brain tumors, and three metastatic bronchogenic carcinomas. All patients had received some form of neurosurgical treatment. Subtotal tumor resections were performed in 22 cases, four having been operated on for a second time. In four other cases, because of deep-seated or multiple metastatic disease, the diagnosis was made by other means. All degrees of neurological impairment were found on the initial evaluation and "staging." Ten patients were considered Stage 1 (asymptomatic), eight Stage 2, six Stage 3, and two Stage 4. There were 113 courses of CCNU given during the 1 89 years of this study. Seventeen patients received initial doses of 130 mg/m 2, eight 150 mg/m 2, and one 100 mg/m 2. Patients treated received up to 11 doses of CCNU; 10 completed five courses, and five completed seven.
Initial Clinical Response
The clinical response to the first course of therapy is summarized in Table 5 . All 10 patients who were Stage 1 prior to chemotherapy continued asymptomatie and were noted as in a state of "continued wellbeing." Six of the 16 previously symptomatic patients (Stages 2, 3, and 4) responded with a remission. The remission rate was found to be 37% for all patients in the study and 43% for all with primary brain tumors regardless of prior radiotherapy. Patients in remission showed marked improvement in motor function, decrease in dysphasia, or lessening of cerebellar abnormalities. One noteworthy response was in a patient treated with corticosteroids, classified as Stage 4. He became entirely asymptomatic (Stage 1 ) 3 weeks after therapy. This improvement continued through most of his second course and permitted a decrease in corticosteroids.
Response to Subsequent Doses and Clinical Follow-up
Twenty-four patients received two or more courses of chemotherapy; the initial progression-free intervals are shown in Table 5 . The progression-free interval represented the length of time before progression of clinical disease was noted. Patients who progressed initially were excluded from analysis. The intervals for patients who had not yet progressed at the time of this analysis are signified with a "plus." Only three of the 10 patients classified as in a state of "continued wellbeing" after the first course progressed, and the median progression-free interval was 11+ months. The median progression-free intervals for patients initially showing a remission and no change were 5 and 4 months respectively. Once progression was noted, additional therapy failed to reverse this phenomenon, and with one exception all patients died within 2 months from the time progression was first observed.
Analysis of survival in Phase 2 studies is difficult as patients entered the study at different times during the course of their disease. Survival details are shown in Table 6 .
Analysis of serial brain scans taken on all patients before and after each course of therapy gave disappointing results. Changes visualized radioisotopically often did not correspond to simultaneous clinical evaluation. A more detailed analysis of these results will be reported separately. Lumbar puncture often showed an increase in CSF pressure consistent with clinically progressive disease; however, analysis of CSF cells, glucose, and total protein content did not appear to contribute valuable information.
Fifteen patients died while receiving CCNU. Postmortem examinations were performed in 10 cases; tumor-related deaths courses of CCNU at due to intracranial herniation of direct tumor involvement of vital brain centers accounted for six of these 10. One patient died unexpectedly of a massive pulmonary embolus.
Three cases were considered possible drug-related deaths and are discussed under toxicity. In all five cases without autopsy verification the clinical cause of death was intracranial herniation, and all were considered tumor-related since platelet counts were greater than 100,000/ mm 3 at the time of death.
Toxicity
The immediate toxic effect from CCNU administration was nausea and vomiting in about 70% of patients, starting 4 to 6 hours after treatment. In the majority of these cases vomiting persisted for several hours and then subsided. Treatment with antiemetics prior to or following drug ingestion did not completely eliminate nausea and vomiting but appeared to lessen the severity. Infrequently, patients complained of a moderate amount of anorexia throughout an entire course, but in only one case was actual weight loss documented. Also, rare complaints of fatigue were noted, usually coinciding with the interval of platelet depression.
Delayed hematological toxicity was the most obvious side effect of CCNU therapy; transient thrombocytopenia was the treatment and dose-limiting factor. During the first course of therapy, platelet count 
* CW = continued well-being; R = remission; NC = no change; P = progression. bone marrow examination, performed on most patients before each course, failed to reveal any change that significantly predicted subsequent hematological toxicity. Of the three patients whose deaths were considered possibly drug-related, one had marked thrombocytopenia (21,000/mm z) and died of hemorrhage into a cerebellar metastasis. Thirty-six courses of CCNU in 13 other patients showed platelet nadirs of less than 50,000/mm 3, yet no other case of intracranial hemorrhage was ever observed. The second death was due to pseudomonas sepsis secondary to diverticulitis in a patient with moderate leukopenia (1600/mmZ). The third death was considered to be both tumor-and drug-related. General central nervous system deterioration plus resolving aplastic anemia, requiring multiple platelet FIG. 1. The mean platelet counts for 10 patients over five courses of CCNU therapy are plotted against the post-treatment interval and represented as five interconnected graphs. Note the lower platelet nadirs for the fourth and fifth courses, and the progressive increase in duration of platelet depression < 150,000/mm 3. and RBC transfusions during his fifth course of CCNU, led to sepsis and death. Only one other patient in the entire study ever developed a platelet count below 10,000/mma; he received prophylactic platelet transfusions during his seventh course. No evidence of hemorrhage was observed in either case.
Mild transient elevations of SGOT, LDH, and alkaline phosphatase were noted in about one-half of the patients. These enzyme levels rose more or less synchronously during each course and tended to return to normal prior to the next treatment. In addition, the abnormalities appeared to become slightly more severe on subsequent courses, but were rarely greater than three times the upper limits of normal. No abnormalities in bilirubin, BUN, uric acid, protein, or calcium could be attributed to the CCNU therapy 9
Discussion
In this Phase 2 study the remission rate for all patients was 37% and compares favorably with the remission rate of 40% to 50% observed using the earlier nitrosourea BCNU. TM The slightly lower response rate found in this study may be the result of more strict criteria for remission as defined by the CNS staging system. It is noteworthy that patients in all stages of progression of disease were represented in the remission 5 category. This seems to indicate that CCNU may be of benefit regardless of the patient's pretreatment status. The exact starting point of improvement was gradual and not typical of the type of immediate response often seen with the effective use of corticosteroid therapy for cerebral edema. Usually 2 to 4 weeks after a dose of CCNU, both the patient and his doctors became gradually aware that there was improvement taking place. Patients who achieved remission continued in an improved state for up to 1 /~ year, with a median of 5 months. It is + 6 difficult to evaluate the actual tumor effect in those cases initially classified as "no change." Since most symptomatic patients had progressive disease when first seen, the observation of no further progression in disease status over the 6 to 8 weeks after the first course might well reflect a halted or slowed progression and a positive response.
In any case, these patients have remained progression-free for up to 1 year after therapy and have a median postoperative survival of 13 months.
Patients initially classified as Stage 1 did not have clinically measurable abnormalities. Nevertheless, they had a progressionfree interval of 11 + months, with a range of up to 21 months, and only three of 10 cases showed progression. The median postoperative survival had been 15+ months to date. This indicates that treatment of these asymptomatic patients may be of considerable value. Most patients in this study were continued on treatment in the belief that this therapy was of value. However, once progression was noted, there was no subsequent improvement in 15 patients, and the clinical status usually deteriorated rapidly despite further CCNU therapy. Thus, once progression is noted, further therapy with CCNU appears to be of little value.
The new CNS disease staging system we have developed permits the practical clinical evaluation of therapy in a mixed population of brain tumor patients who were treated at different stages of progressive disease. It provides a reliable measure of the degree of impairment at any time. Comparing the stages after therapy with the pretreatment evaluation has permitted us to assess CCNU efficacy in these cases. The system appears sensitive enough to reflect significant changes in disease pattern as a change in disease status. The disease stages purposely overlap to a small extent in order that the system not be so sensitive as to allow minor insignificant changes to effect a change in disease status. Differences in staging as recorded by different examiners were rare when the evaluations were made on the same day. The system requires the examiner to place each patient in a specific category, taking into account all pertinent factors. A single finding that seems out of proportion to the overall clinical impression does not invalidate the system, and the vast majority of patients can be classified. A valid staging system should show a relationship between the initial staging and subsequent survival, as in Table 6 . As the initial stage indicates progressively more severe disease, the median postoperative as well as post-treatment survival of staged patients becomes progressively shorter.
CCNU was well tolerated. Oral administration seems preferable to the intravenous route used for its relative BCNU because of the latter's inevitable vein sclerosis. Prolonged hematological suppression was the most consistent dose-limiting side effect of CCNU, with thrombocytopenia as the most marked effect. Earlier studies 6 noted that a dose of 130 mg/m 2 was well tolerated, but did not note cumulative toxicity. However, we found cumulative hematological toxicity was found after prolonged therapy. To avoid cumulative complications, patients who had exhibited severe bone marrow depressions were subsequently treated with reduced doses or dropped from the protocol.
In contradistinction to animal studies, hepatic and renal toxicity was not present/ Serial chemistries showed only mild transient abnormalities in SGOT, LDH, and alkaline phosphatase, probably reflecting minor hepatic dysfunction. Although this toxicity was occasionally progressive, it was not dose-limiting.
The occurrence of thrombocytopenia and hemorrhage into a brain tumor is well known. However, despite the apparent predisposition imposed by thrombocytopenia in this study, only one patient had an intracranial hemorrhage. We feel, therefore, that the conservative approach to prophylactic platelet transfusion used here (transfusion only if the platelet count falls to or below 10,000/mm 3) appears valid and minimizes the well-known potential hazards of multiple platelet transfusions. The platelet depression observed using 130 to 150 mg/m 2 of CCNU appeared less severe than that seen with BCNU in a comparable study using doses of 80 to 100 mg/m 2 per day on three successive days. ~ In the latter study, nine of 16 patients had nadirs of less than 30,000/mm ' during their first course, whereas only two of 26 patients receiving CCNU showed platelet depressions of less than 30,000/mm 3 during their first course of therapy.
Summary
The initial clinical response to CCNU chemotherapy, with a 37% remission rate for all symptomatic patients, has been encouraging. The treatment of asymptomatic patients may also be of considerable value. Once progression of CNS disease is noted, further therapy with CCNU appears to be of little benefit. Delayed, reversible thrombocytopenia has been the most severe toxic manifestation noted, and definitive cumulative hematological toxicity affecting all three bone marrow elements was observed during long-term therapy. The treatment schedule utilized in this study, however, has kept druginduced complications to a minimum. Our initial experience with CCNU is sufficiently encouraging to support further study of this chemotherapeutic agent.
